Telitacicept completed domestic phase II clinical study on IgA Nephropathy

2021-08-10

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

2021-08-09

First clinical trial permit in Australia of Remegen! RC118, an ADC drug targeting the Claudin18.2

2021-07-30

Telitacicept Phase II clinical data on IgA Nephropathy presented at the Annual meeting of the American Society of Nephrology

2021-11-17

RC48-ADC appeared on ASCO 2021 meeting again and brought exciting clinical data

2021-06-05

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

2020-06-17
1 / 0
Twitter Facebook 微博

Company Wechat

© All Right Reserved .  ICP:鲁ICP备11031710号-1